Jun R Chiong1, Rebecca J Cheung. 1. Department of Medicine, Cardiology Division, Loma Linda University School of Medicine, Loma Linda, California 92354, USA. jchiong@llu.edu
Abstract
BACKGROUND: Heart failure (HF) is a common condition associated with substantial cost, morbidity, and mortality. Because results of clinical trials in the acute decompensated heart failure (ADHF) setting have been mostly neutral, loop diuretics remain the mainstay of treatment. HYPOTHESIS: Loop diuretic use may be associated with unfavorable outcomes. METHODS: A MEDLINE literature search was performed to identify articles relating to heart failure and loop diuretics. The current evidence on the risks and benefits of loop diuretics for the treatment of ADHF is reviewed. RESULTS: Loop diuretics are associated with symptomatic improvements in congestion, urine output, and body weight, but have shown no long-term mortality benefit. Loop diuretics, especially at high doses, are associated with worsened renal function and other poor outcomes. CONCLUSIONS: Loop diuretics still prove useful in HF treatment, but risk-benefit analysis of these agents in the treatment of ADHF requires a well-designed prospective study.
BACKGROUND:Heart failure (HF) is a common condition associated with substantial cost, morbidity, and mortality. Because results of clinical trials in the acute decompensated heart failure (ADHF) setting have been mostly neutral, loop diuretics remain the mainstay of treatment. HYPOTHESIS: Loop diuretic use may be associated with unfavorable outcomes. METHODS: A MEDLINE literature search was performed to identify articles relating to heart failure and loop diuretics. The current evidence on the risks and benefits of loop diuretics for the treatment of ADHF is reviewed. RESULTS: Loop diuretics are associated with symptomatic improvements in congestion, urine output, and body weight, but have shown no long-term mortality benefit. Loop diuretics, especially at high doses, are associated with worsened renal function and other poor outcomes. CONCLUSIONS: Loop diuretics still prove useful in HF treatment, but risk-benefit analysis of these agents in the treatment of ADHF requires a well-designed prospective study.
Authors: Per Wändell; Axel C Carlsson; Xinjun Li; Martin J Holzmann; Jan Sundquist; Kristina Sundquist Journal: J Clin Hypertens (Greenwich) Date: 2020-07-15 Impact factor: 3.738
Authors: Hall Schartum-Hansen; Kjetil H Løland; Gard F T Svingen; Reinhard Seifert; Eva R Pedersen; Jan E Nordrehaug; Øyvind Bleie; Marta Ebbing; Christ Berge; Dennis W T Nilsen; Ottar Nygård Journal: PLoS One Date: 2015-06-01 Impact factor: 3.240
Authors: Igor V Ukrainets; Lyudmila V Sidorenko; Mykola Y Golik; Igor M Chernenok; Lina A Grinevich; Alexandra A Davidenko Journal: Sci Pharm Date: 2018-04-09